Hydrochlorothiazide
Hydrochlorothiazide is a thiazide diuretic taken by mouth. The US label read is for hydrochlorothiazide tablets and lists two uses: adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy (the label also names edema from kidney disease as a use it has been found useful for); and the management of hypertension, as the sole agent or, in the more severe forms of hypertension, to enhance other antihypertensive drugs. The label's separate passage on diuretics in pregnancy was not recorded. Combination products that contain hydrochlorothiazide have their own labels and are not described here.
Also called HCTZ
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 5487; UNII 0J48LPH2TH. MeSH descriptor D006852 is Hydrochlorothiazide. Class: Thiazide Diuretic (FDA established pharmacologic class, RxClass). The label read is the hydrochlorothiazide tablets, Aurobindo Pharma Limited label, effective 2024-06-26 in openFDA (application ANDA040780). Other hydrochlorothiazide labels in openFDA, from other sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 16 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 16
- Phase 3 or 4
- 12
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|
| Phase 2 | 3 | 0 | 0 | 3 |
| Phase 2/3 | 1 | 0 | 0 | 1 |
| Phase 3 | 3 | 1 | 1 | 5 |
| Phase 4 | 3 | 0 | 4 | 7 |
| All phases | 10 | 1 | 5 | 16 |
Conditions these trials study
- Hypertension (high blood pressure)
- Chronic kidney disease (CKD)
- Heart failure
- Cerebral small vessel disease
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- Not reported
Claims and evidence
Context People for whom the US label of hydrochlorothiazide tablets lists an indication: edema (including edema of congestive heart failure), hypertension
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Patients with edema associated with congestive heart failure, hepatic cirrhosis, or corticosteroid and estrogen therapy
- Patients with hypertension
- Excluded
- None stated
The US label of hydrochlorothiazide tablets, in the Aurobindo Pharma Limited version dated 2024-06-26 in openFDA, lists the medicine as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy, and in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
Applies to Recipient not specified People for whom the US label of hydrochlorothiazide tablets lists an indication: edema (including edema of congestive heart failure), hypertension
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0]
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2024-06-26
- Source state
- Current
- Version fingerprint
cc53f95717d74809d63ae95a14078f0ca4d3da6de792140deebbaf4f025c5549- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20240626.
- Retrieved
- Source effective date
- 2024-06-26
- Source state
- Current
- Version fingerprint
cc53f95717d74809d63ae95a14078f0ca4d3da6de792140deebbaf4f025c5549- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
ACCURETIC
No label from the application holder was found in the openFDA label dataset for application NDA020125. This page does not show another labeler's label in its place.
ALDACTAZIDE
No label from the application holder was found in the openFDA label dataset for application NDA012616. This page does not show another labeler's label in its place.
ALDORIL 15
No label from the application holder was found in the openFDA label dataset for application NDA013402. This page does not show another labeler's label in its place.
AMTURNIDE
No label from the application holder was found in the openFDA label dataset for application NDA200045. This page does not show another labeler's label in its place.
ATACAND HCT
No label from the application holder was found in the openFDA label dataset for application NDA021093. This page does not show another labeler's label in its place.
AVALIDE
No label from the application holder was found in the openFDA label dataset for application NDA020758. This page does not show another labeler's label in its place.
BENICAR HCT
No label from the application holder was found in the openFDA label dataset for application NDA021532. This page does not show another labeler's label in its place.
CAPOZIDE 25/15
No label from the application holder was found in the openFDA label dataset for application NDA018709. This page does not show another labeler's label in its place.
DIOVAN HCT
No label from the application holder was found in the openFDA label dataset for application NDA020818. This page does not show another labeler's label in its place.
DUTOPROL
No label from the application holder was found in the openFDA label dataset for application NDA021956. This page does not show another labeler's label in its place.
DYAZIDE
No label from the application holder was found in the openFDA label dataset for application NDA016042. This page does not show another labeler's label in its place.
ESIDRIX
No label from the application holder was found in the openFDA label dataset for application NDA011793. This page does not show another labeler's label in its place.
EXFORGE HCT
No label from the application holder was found in the openFDA label dataset for application NDA022314. This page does not show another labeler's label in its place.
HYDRODIURIL
No label from the application holder was found in the openFDA label dataset for application NDA011835. This page does not show another labeler's label in its place.
HYDROPRES 25
No label from the application holder was found in the openFDA label dataset for application NDA011958. This page does not show another labeler's label in its place.
HYZAAR
No label from the application holder was found in the openFDA label dataset for application NDA020387. This page does not show another labeler's label in its place.
INDERIDE LA 80/50
No label from the application holder was found in the openFDA label dataset for application NDA019059. This page does not show another labeler's label in its place.
INDERIDE-40/25
No label from the application holder was found in the openFDA label dataset for application NDA018031. This page does not show another labeler's label in its place.
INZIRQO
No label from the application holder was found in the openFDA label dataset for application NDA219141. This page does not show another labeler's label in its place.
LOPRESSOR HCT
No label from the application holder was found in the openFDA label dataset for application NDA018303. This page does not show another labeler's label in its place.
LOTENSIN HCT
No label from the application holder was found in the openFDA label dataset for application NDA020033. This page does not show another labeler's label in its place.
MAXZIDE
No label from the application holder was found in the openFDA label dataset for application NDA019129. This page does not show another labeler's label in its place.
MICARDIS HCT
No label from the application holder was found in the openFDA label dataset for application NDA021162. This page does not show another labeler's label in its place.
MICROZIDE
No label from the application holder was found in the openFDA label dataset for application NDA020504. This page does not show another labeler's label in its place.
MODURETIC 5-50
No label from the application holder was found in the openFDA label dataset for application NDA018201. This page does not show another labeler's label in its place.
MONOPRIL-HCT
No label from the application holder was found in the openFDA label dataset for application NDA020286. This page does not show another labeler's label in its place.
NORMOZIDE
No label from the application holder was found in the openFDA label dataset for application NDA019046. This page does not show another labeler's label in its place.
ORETIC
No label from the application holder was found in the openFDA label dataset for application NDA011971. This page does not show another labeler's label in its place.
ORETICYL 25
No label from the application holder was found in the openFDA label dataset for application NDA012148. This page does not show another labeler's label in its place.
PRINZIDE
No label from the application holder was found in the openFDA label dataset for application NDA019778. This page does not show another labeler's label in its place.
SER-AP-ES
No label from the application holder was found in the openFDA label dataset for application NDA012193. This page does not show another labeler's label in its place.
SERPASIL-ESIDRIX #1
No label from the application holder was found in the openFDA label dataset for application NDA011878. This page does not show another labeler's label in its place.
TEKTURNA HCT
No label from the application holder was found in the openFDA label dataset for application NDA022107. This page does not show another labeler's label in its place.
TEVETEN HCT
No label from the application holder was found in the openFDA label dataset for application NDA021268. This page does not show another labeler's label in its place.
TIMOLIDE 10-25
No label from the application holder was found in the openFDA label dataset for application NDA018061. This page does not show another labeler's label in its place.
TRIBENZOR
No label from the application holder was found in the openFDA label dataset for application NDA200175. This page does not show another labeler's label in its place.
UNIRETIC
No label from the application holder was found in the openFDA label dataset for application NDA020729. This page does not show another labeler's label in its place.
VASERETIC
No label from the application holder was found in the openFDA label dataset for application NDA019221. This page does not show another labeler's label in its place.
ZESTORETIC
No label from the application holder was found in the openFDA label dataset for application NDA019888. This page does not show another labeler's label in its place.
ZIAC
No label from the application holder was found in the openFDA label dataset for application NDA020186. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
- Approval
NDA011793 - Approval
NDA011835 - Approval
NDA011878 - Approval
NDA011971 - Approval
NDA012148 - Approval
NDA012193 - Approval
NDA012616 - Approval
NDA013402 - Approval
NDA016042 - Approval
NDA011958 - Approval
NDA018031 - Approval
NDA018201 - Approval
NDA018061 - Approval
NDA018709 - Approval
NDA019129 - Approval
NDA018303 - Approval
NDA019059 - Approval
NDA019221 - Approval
NDA019046 - Supplemental approval
NDA018061 - Supplemental approval
NDA019129 - Approval
NDA019778 - Approval
NDA019888 - Supplemental approval
NDA018031 - Supplemental approval
NDA018709 - Approval
NDA020033 - Supplemental approval
NDA011835 - Approval
NDA020186 - Supplemental approval
NDA019778 - Supplemental approval
NDA019888 - Supplemental approval
NDA016042 - Approval
NDA020286 - Approval
NDA020387 - Supplemental approval
NDA019221 - Approval
NDA020504 - Approval
NDA020729 - Approval
NDA020758 - Approval
NDA020818 - Approval
NDA020125 - Approval
NDA021093 - Approval
NDA021162 - Approval
NDA021268 - Supplemental approval
NDA020818 - Approval
NDA021532 - Supplemental approval
NDA020387 - Supplemental approval
NDA020387 - Supplemental approval
NDA020387 - Supplemental approval
NDA020818 - Approval
NDA021956 - Supplemental approval
NDA020758 - Approval
NDA022107 - Supplemental approval
NDA020818 - Supplemental approval
NDA018061 - Approval
NDA022314 - Supplemental approval
NDA022107 - Approval
NDA200175 - Approval
NDA200045 - Approval
NDA219141
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists the management of hypertension as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified People for whom the US label of hydrochlorothiazide tablets lists an indication: edema (including edema of congestive heart failure), hypertension
The US label of hydrochlorothiazide tablets, in the Aurobindo Pharma Limited version dated 2024-06-26 in openFDA, lists the medicine as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy, and in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists adjunctive therapy in edema associated with congestive heart failure as an indication: Heart failure
Applies to Recipient not specified People for whom the US label of hydrochlorothiazide tablets lists an indication: edema (including edema of congestive heart failure), hypertension
The US label of hydrochlorothiazide tablets, in the Aurobindo Pharma Limited version dated 2024-06-26 in openFDA, lists the medicine as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy, and in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 40
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 2 brand...
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 2 brand...
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 3 brand...
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 4 brand...
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
Registry trials 16
Record details
- Record id
cardio:hydrochlorothiazide- Content hash
0b2f5bf56f0ca2a1367a7afa16c5d7ca76a978812607810c987c4427ad322e45